Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in preclinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trial
{{output}}
Aims: Previous studies have shown that individuals with a hypertrophic cardiomyopathy (HCM) pathogenic variant (PV) or likely pathogenic variant (LPV) without a HCM phenotype (PV/LPV carrier) have decreased myocardial external ef... ...
